July 9, 2020 / 1:00 PM / a month ago

BRIEF-Alimera Sciences Initiates Landmark New Day Clinical Trial To Evaluate Iluvien As Baseline Therapy For Diabetic Macular Edema

July 9 (Reuters) - Alimera Sciences Inc:

* ALIMERA SCIENCES INITIATES LANDMARK NEW DAY CLINICAL TRIAL TO EVALUATE ILUVIEN® AS BASELINE THERAPY FOR DIABETIC MACULAR EDEMA

* ALIMERA SCIENCES INC - EXPECTS TO INCUR APPROXIMATELY $13.5 MILLION OVER NEXT THREE TO FOUR YEARS ASSOCIATED WITH NEW DAY STUDY Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below